<DOC>
	<DOCNO>NCT00879086</DOCNO>
	<brief_summary>The purpose study patient advance breast cancer compare incidence severity neuropathy adverse event two treatment group ( eribulin versus ixabepilone ) use National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE version 3.0 ) grading .</brief_summary>
	<brief_title>A Study Comparing Eribulin Mesylate Ixabepilone Causing Exacerbating Neuropathy Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Inclusion criterion : 1 . Female subject confirm locally recurrent metastatic carcinoma breast receive prior taxane therapy least one prior cytotoxic chemotherapy regimen advance disease . Exclusion criterion : 1 . Subjects receive prior ixabepilone therapy . 2 . Subjects prior participation eribulin clinical study , even assign eribulin treatment . 3 . Subjects preexist neuropathy Grade great equal 2 . 4 . Subjects history diabetes mellitus Type 1 2 . 5 . Subjects bilateral mastectomy include bilateral axillary lymph node dissection . 6 . Subjects miss digit require vibration assessment . 7 . Subjects concurrent disease condition would expect interfere neuropathy assessment , may include vitamin deficiency , sequelae cerebrovascular disease , thyroid insufficiency , lumbar cervical radiculopathy , alcoholic inflammatory neuropathy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Oncology</keyword>
</DOC>